ImmunoCellular Therapeutics' Andrew Gengos Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - December 17, 2015) - Los Angeles-based ImmunoCellular Therapeutics Ltd.(NYSE MKT: IMUC) is on the verge of a pivotal Phase 3 trial with its dendritic cell immunotherapy for brain cancer. It's an extraordinary and exciting time for CEO Andrew Gengos, who is a veteran biotech executive. In this interview with The Life Sciences Report, Gengos discusses his firm's recently reported Phase 2 data in glioblastoma, as well as the company's strategy for the upcoming registration trial.

The Life Sciences Report : You and your team at ImmunoCellular Therapeutics Ltd. are studying ICT-107 (autologous dendritic cells pulsed with immunogenic peptides from six tumor-associated antigens) as an immunotherapy targeting glioblastoma multiforme (GBM), a very serious and very tough indication. This is your most advanced program, and the study is in newly diagnosed patients who have had surgical resection and chemo-radiation, but are not as worn down immunologically as patients treated over a prolonged period. Do you think you'll have a more durable result in this population?

Andrew Gengos: We hope so. Obviously, we're speculating, but we have two things in mind when we're selecting an indication like newly diagnosed glioblastoma. The first is that, when you're talking about an immunotherapy that utilizes the patient's immune system to attack cancer, it's important the patient be able to mount an immune response. If a patient is immune-depleted by chemotherapy, you have to question whether that's the best setting to test an immunotherapy in. Newly diagnosed glioblastoma patients, despite standard-of-care chemo-radiation treatment, are still typically able to mount an immune response following administration of our immunotherapy. The second key point is…

Continue reading this interview: An Immunotherapeutic Approach to Glioblastoma: ImmunoCellular Therapeutics' CEO Andrew Gengos

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

DISCLOSURE:

ImmunoCellular Therapeutics Ltd. paid Streetwise Reports to conduct, produce and distribute this interview. Andrew Gengos had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Gengos and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.